ARTICLE | Company News
Cadence sales and marketing update
February 13, 2012 8:00 AM UTC
Cadence recalled lot V005710 of Ofirmev IV acetaminophen in the U.S. due to the detection of an unidentified, visible particle in one vial during routine stability testing. Cadence said fewer than 1,000 vials from the lot remain in the market. Cadence did not receive reports of adverse events associated with the product. Cadence launched Ofirmev in the U.S. last year to treat pain and fever (see BioCentury, Jan. 24, 2011). ...